Patents by Inventor Ian A. McDonald
Ian A. McDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8426587Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: GrantFiled: November 19, 2008Date of Patent: April 23, 2013Assignee: Pharmaxis Ltd.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
-
Publication number: 20100298330Abstract: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: ApplicationFiled: November 19, 2008Publication date: November 25, 2010Applicant: PHARMAXIS LTD.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
-
Patent number: 6956049Abstract: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds.Type: GrantFiled: August 31, 1999Date of Patent: October 18, 2005Assignee: Merck & Co., Inc.Inventors: Nicholas D. P. Cosford, Ian A. McDonald, Stephen D. Hess, Mark A. Varney
-
Patent number: 6632823Abstract: In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of modulating acetylcholine receptors. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.Type: GrantFiled: December 22, 1997Date of Patent: October 14, 2003Assignee: Merck & Co., Inc.Inventors: Jean-Michel Vernier, Nicholas D. P. Cosford, Ian A. McDonald
-
Patent number: 6316490Abstract: In accordance with the present invention, a novel class of substituted aryl compounds (containing ether, ester, amide, ketone or thioether substitution) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect, compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g., 3H-nicotine, from mammalian neuronal membrane binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.Type: GrantFiled: July 8, 1997Date of Patent: November 13, 2001Assignee: Merck & Co., Inc.Inventors: Jean-Michel Vernier, Ian A. McDonald
-
Patent number: 6017887Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: January 25, 2000Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5969100Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: March 13, 1995Date of Patent: October 19, 1999Assignee: SIBIA Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5877202Abstract: The present invention relates to novel indole derivatives useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing a neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.Type: GrantFiled: January 31, 1996Date of Patent: March 2, 1999Inventors: Alan J. Bitonti, Ian A. McDonald, Francesco G. Salituro, Jeffrey P. Whitten, Esa T. Jarvi, Paul S. Wright
-
Patent number: 5872101Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: February 16, 1999Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5863902Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; RB is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: January 26, 1999Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5723477Abstract: The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites.Type: GrantFiled: June 7, 1995Date of Patent: March 3, 1998Assignee: Sibia Neurosciences, Inc.Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
-
Patent number: 5710324Abstract: The present invention is directed to a new class of compound which are useful as inhibitors of the biosynthesis of nitric oxide.Type: GrantFiled: October 4, 1994Date of Patent: January 20, 1998Assignee: Merrell Pharmaceuticals Inc.Inventors: Jeffrey P. Whitten, Ian A. McDonald, Laurie E. Lambert, Niall S. Doherty
-
Patent number: 5703100Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.Type: GrantFiled: June 7, 1995Date of Patent: December 30, 1997Assignee: SIBIA Neurosciences, Inc.Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
-
Patent number: 5606063Abstract: The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.Type: GrantFiled: June 5, 1995Date of Patent: February 25, 1997Assignee: Merrell Pharmaceuticals Inc.Inventors: Boyd L. Harrison, Bruce M. Baron, David M. Stemerick, Ian A. McDonald
-
Patent number: 5594011Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.Type: GrantFiled: November 10, 1994Date of Patent: January 14, 1997Assignee: SIBIA Neurosciences, Inc.Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
-
Patent number: 5567710Abstract: In accordance with the present invention, there is provided a class of polycyclic fused ring compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.Type: GrantFiled: October 13, 1994Date of Patent: October 22, 1996Assignee: SIBIA Neurosciences, Inc.Inventors: Jeffrey P. Whitten, Ian A. McDonald, Jean-Michel Vernier
-
Patent number: 5559143Abstract: The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.Type: GrantFiled: October 7, 1994Date of Patent: September 24, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Ian A. McDonald, Ronald C. Bernotas, Mark W. Dudley, Jeffrey S. Sprouse
-
Patent number: 5547991Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.Type: GrantFiled: July 17, 1995Date of Patent: August 20, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz
-
Patent number: 5489579Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.Type: GrantFiled: February 4, 1994Date of Patent: February 6, 1996Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Ian A. McDonald, Bruce M. Baron
-
Patent number: 5470870Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.Type: GrantFiled: June 17, 1994Date of Patent: November 28, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron